Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Boucher

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
CNS Spectrums|February 28, 2014
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorderClaudio N Soares, Jean Endicott, Matthieu Boucher, et al.
Journal of Cardiovascular Pharmacology|April 13, 2004
Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathwayMatthieu Boucher, Stéphanie Pesant, Stéphanie Falcao, et al.
International Clinical Psychopharmacology|March 4, 2014
Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxineRaymond W Lam, Jean Endicott, Ming-Ann Hsu, et al.
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2017
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysisRaymond W Lam, Dalia B Wajsbrot, Ellen Meier, et al.
Journal of Cardiovascular Pharmacology|April 12, 2005
Sustained cardioprotection afforded by A2A adenosine receptor stimulation after 72 hours of myocardial reperfusionMatthieu Boucher, Boubacar Pasto Wann, Sevan Kaloustian, et al.
Journal of Clinical Psychopharmacology|February 29, 2024
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled StudiesRoger S McIntyre, Suzy Bubolic, Zhen Zhang, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 27, 2007
Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heartErhe Gao, Matthieu Boucher, J Kurt Chuprun, et al.
Journal of Affective Disorders|July 12, 2014
Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorderJean Endicott, Raymond W Lam, Ming-Ann Hsu, et al.
Journal of Clinical Psychopharmacology|June 29, 2021
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for DepressionSigal Zilcha-Mano, Xuemei Wang, Dalia B Wajsbrot, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
CNS Spectrums|February 28, 2014
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorderClaudio N Soares, Jean Endicott, Matthieu Boucher, et al.
Journal of Cardiovascular Pharmacology|April 13, 2004
Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathwayMatthieu Boucher, Stéphanie Pesant, Stéphanie Falcao, et al.
International Clinical Psychopharmacology|March 4, 2014
Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxineRaymond W Lam, Jean Endicott, Ming-Ann Hsu, et al.
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2017
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysisRaymond W Lam, Dalia B Wajsbrot, Ellen Meier, et al.
Journal of Cardiovascular Pharmacology|April 12, 2005
Sustained cardioprotection afforded by A2A adenosine receptor stimulation after 72 hours of myocardial reperfusionMatthieu Boucher, Boubacar Pasto Wann, Sevan Kaloustian, et al.
Journal of Clinical Psychopharmacology|February 29, 2024
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled StudiesRoger S McIntyre, Suzy Bubolic, Zhen Zhang, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 27, 2007
Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heartErhe Gao, Matthieu Boucher, J Kurt Chuprun, et al.
Journal of Affective Disorders|July 12, 2014
Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorderJean Endicott, Raymond W Lam, Ming-Ann Hsu, et al.
Journal of Clinical Psychopharmacology|June 29, 2021
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for DepressionSigal Zilcha-Mano, Xuemei Wang, Dalia B Wajsbrot, et al.
Pageof 5